DVC Stem's IRB-approved mesenchymal stem cell protocol is currently priced at $25,000 USD. He continues to research alternative therapies for various medical conditions, and with IRB certified clinical trials, has treated local and international patients for Multiple Sclerosis (MS), Chronic Low Grade Inflammation (which is part of the overall Aging Process), and many other degenerative conditions. Cona, is a pioneer in regenerative cell therapy, providing the first stem cell treatments in the Cayman Islands more than a decade ago.
The cost of stem cell therapy at DVC StemĭVC Stem is an innovative stem cell therapy clinic in the Cayman Islands. When considering a potentially life-changing treatment, prospective patients should be weighing these other important factors, in addition to cost, when determining the best location for experimental procedures. Make sure to know how many cells you are getting, where those cells come from, if they are viable, is the clinic/lab is regulated, and ask for as detailed info to be provided as possible. Patients must do their research and ask as many questions as they can before financially committing to treatment. Stem cell therapy cost can range anywhere between $5000 - $50,000. The cost of a site injection for an orthopedic condition will be significantly different than an intravenous treatment for an autoimmune condition. It is also important to note that the cost of stem cell therapy will vary depending on the type of treatment needed. The source of stem cells (umbilical cord tissue, adipose tissue, bone marrow, etc.).Where the laboratory is located (for cell expansion).The quality of the cells (are the ethically sourced, viable & regulated?).Stem cell therapy cost can be influenced by: Treatment cost will vary dramatically depending on a variety of different factors. Additional clinical trials will be required to confirm the results of this preliminary trial.Stem cell therapy can costs can range anywhere from $5000-$50,000 USD. The authors acknowledge the limitations of the results, considering the small size of the clinical trial, which was also unblinded and uncontrolled. 'Similar results with stem cells in patients with stroke increases our confidence that this approach may be clinically useful,' said senior co-author Professor Jeffery Kocsis from Yale.
In addition, no substantial side effects were reported.
All but one of the patients demonstrated motor and sensory improvements after six months of infusion.
The results of the phase 2 clinical trial involving 13 patients who had sustained non-penetrating spinal cord injuries were published in the journal of Clinical Neurology and Neurosurgery. By intravenously infusing the patients' own stem cells, derived from their bone marrow, this therapy was expected to affect several areas of the central nervous system, including the brain and blood vessels. Researchers from Yale and Sapporo Medical University in Japan used mesenchymal stem cells which can differentiate into different types of cells. 'Now we have a hint, in humans, that it may be possible.' 'The idea that we may be able to restore function after injury to the brain and spinal cord using the patient's own stem cells has intrigued us for years,' said senior co-author Professor Stephen Waxman of Yale School of Medicine in Connecticut. In the trial, patients treated with intravenous infusion of their own stem cells showed significant improvement in key functions, such as the ability to walk or use their hands. However, treatment options are limited to physical rehabilitation programmes. Spinal cord injuries are associated with a permanent loss of movement and physical sensations due to nerve damage. Stem cell therapy significantly improved spinal cord injuries in a small clinical trial.